Data are becoming available for both the JAK/STAT pathway and the IL blocking, along with the investigation of the other pathways involved in AD pathogenesis, such as TSLP and OX40 blockade, resulting in novel insights into the immunological components of the disorder, as well as a new era of treatment options for the patients. This evidence concerns the gene TSLP and Alzheimer disease.